Welcome to our dedicated page for Lensar news (Ticker: LNSR), a resource for investors and traders seeking the latest updates and insights on Lensar stock.
LENSAR, Inc. (Nasdaq: LNSR) is a commercial-stage medical device and global medical technology company focused on advanced laser systems for the treatment of cataracts and the management of astigmatism. News about LENSAR often centers on its ALLY Robotic Cataract Laser System, financial performance, and the company’s pending acquisition by Alcon Research, LLC.
Regular earnings releases provide updates on quarterly revenue, procedure volumes performed on LENSAR’s installed base of laser systems, and the mix between system sales and recurring revenue from procedures, leases, and service. These reports also discuss non-GAAP metrics such as EBITDA and Adjusted EBITDA, along with commentary on operational initiatives and utilization of the ALLY system in the United States and abroad.
Another recurring news theme is corporate and capital markets activity. LENSAR has announced a definitive merger agreement under which Alcon intends to acquire the company, including the ALLY Robotic Cataract Laser Treatment System, Streamline software technology, and the LENSAR legacy laser system. Subsequent updates describe stockholder approval of the merger proposal and ongoing regulatory review, including interactions with the U.S. Federal Trade Commission.
LENSAR also issues announcements related to equity compensation, such as inducement grants of restricted stock units and stock options to newly hired non-executive employees under its Employment Inducement Incentive Award Plan. These items provide insight into hiring and compensation practices. Investors and observers who follow LNSR news can use this page to review earnings releases, merger-related developments, and governance and compensation updates in one place.
LENSAR, Inc. (NASDAQ: LNSR) reported preliminary unaudited revenue of approximately $10.2 million for Q4 2022, down from $11.2 million in the same quarter of 2021, attributed to lower procedure revenue in South Korea. However, Q4 revenue shows a 32% increase from Q3 2022. Total revenue for 2022 reached about $35.4 million, slightly up from $34.5 million in 2021. The company installed ten ALLY Systems in 2022, with contracts for six more signed for installation in H1 2023. Cash and cash equivalents were approximately $14.7 million as of December 31, 2022, reflecting the company's ongoing transition to its next-generation technology.
LENSAR, a medical technology company specializing in femtosecond laser surgical solutions for cataracts, announced that CEO Nick Curtis will present at two investor conferences. The presentations include the BTIG Ophthalmology Day on November 29 at 3:00 p.m. ET and the Piper Sandler 34th Annual Healthcare Conference on November 30 at 2:50 p.m. ET. The live presentation can be accessed on LENSAR's website, with the Piper Sandler event available for a month afterward.
LENSAR, a leader in advanced laser surgical solutions for cataracts, reported its Q3 2022 results, showing total revenue of $7.7 million, a 6% decline from $8.3 million in Q3 2021. Despite a 46% drop in international procedures, U.S. volumes rose 9%. Operating expenses decreased, contributing to a reduced net loss of $4 million ($0.39 per share), down from $6.2 million ($0.65 per share) a year earlier. The ALLY System's U.S. launch is pivotal, with strong surgeon feedback. Cash reserves as of September 30, 2022, stood at $19.3 million, providing operational funding through 2024.
LENSAR, Inc. (NASDAQ: LNSR) will release its third quarter 2022 financial results before market open on November 9, 2022. A conference call to discuss these results and recent corporate developments is scheduled for 8:30 am ET on the same day. LENSAR specializes in advanced femtosecond laser surgical solutions for cataracts, utilizing its next-generation ALLY™ Adaptive Cataract Treatment System. This innovative system integrates proprietary imaging with a dual-pulse femtosecond laser, designed to enhance operational efficiencies in cataract surgeries.
LENSAR, Inc. (NASDAQ: LNSR), a medical technology firm specializing in femtosecond laser solutions for cataract treatment, has announced its application for certification of the ALLY™ Adaptive Cataract Treatment System in the European Union. Following FDA clearance in June 2022 and a successful U.S. launch, this step aims to expand global access to ALLY. The system enhances cataract surgery efficiency by integrating Adaptive Intelligence™ to optimize surgical parameters. If certified, LENSAR plans to utilize a distributor network for its EU launch.
LENSAR, Inc. (NASDAQ: LNSR) has announced the first commercial use of its ALLY™ Adaptive Cataract Treatment System at The Eye Institute of West Florida. Dr. Robert Weinstock performed 15 surgeries using the ALLY system, showcasing its advanced capabilities aimed at enhancing cataract surgery efficiency and patient outcomes. Since receiving FDA clearance in June 2022, LENSAR plans to install 8 to 12 ALLY systems as part of a controlled launch. The system's design focuses on improving the surgical experience for both patients and surgeons, positioning LENSAR for growth in the cataract treatment market.
LENSAR, a medical technology company, announced FDA clearance for its ALLY Adaptive Cataract Treatment System, marking a significant milestone. In Q2 2022, total revenue increased to $8.0 million, up 1% from Q2 2021, driven by a rise in U.S. procedure volumes despite lower LENSAR Laser System sales. Operating expenses rose by 37% to $7.6 million, attributed to higher marketing costs. The net loss for Q2 2022 widened to $6.8 million, compared to $4.4 million the previous year. Cash reserves stood at $25.2 million, with sufficient funds projected to sustain operations into 2024.
LENSAR, Inc. (NASDAQ: LNSR) will release its second quarter 2022 financial results on August 8, 2022, before market open. A conference call and webcast will follow at 8:30 am ET on the same day, where management will discuss the financial results and corporate highlights. The company specializes in advanced femtosecond laser surgical solutions for cataracts, notably with its ALLY™ Adaptive Cataract Treatment System, which enhances operational efficiency and surgical outcomes.
LENSAR, Inc. (NASDAQ: LNSR) announced FDA 510(k) clearance for its innovative ALLY Adaptive Cataract Treatment System. This system enables seamless femtosecond-laser-assisted cataract surgery (FLACS) in a single sterile environment. The company plans to begin a controlled launch in Q3 2023, with broader availability anticipated later this year. The ALLY System's technology includes Adaptive Intelligence to optimize cataract procedures, aiming to enhance surgical efficiency and patient outcomes. Over 125 surgeons have already had hands-on experience with the system, indicating positive reception.
LENSAR, Inc. (Nasdaq: LNSR) reported a 33% revenue increase to $9.3 million for Q1 2022, driven by a 38% rise in procedure volume to 38,901. The CEO expressed optimism about the forthcoming ALLY Adaptive Cataract Treatment System, which has received FDA acceptance for its 510(k) application and is expected to launch this year. However, the net loss widened to $6.7 million from $5.2 million year-over-year. R&D expenses surged 74% due to ALLY's development costs, while cash reserves decreased to $29 million, indicating the need for careful cash management going forward.